



Newsletter from Emotra AB (publ)
Göteborg, 30 January, 2020

Emotra moves into the AstraZeneca BioVentureHub and manuscript has been submitted

At the end of 2019, Emotra AB (“Emotra”) were interviewed by the management team at AstraZeneca BioVentureHub, after which we were offered space at the pharmaceutical company’s research facility in Mölndal, Sweden. Our decision to move there was motivated by a number of positive factors, but a special focus on interaction and collaboration was important, given Emotra’s new research focus.

In the scientific area, an important step for our EUDOR-A study has been taken, as we have now submitted our paper to a scientific journal. At the same time, we continue planning future studies to verify the new indication area and seek new collaboration partners for EDOR®-Test.

Lately, we have been initiating new scientific collaborations in order to verify the first results, which indicate that hyporeactive, depressed patients run an increased risk of depression relapse. At the same time, this new data opens new doors for other research about hyporeactivity which will also allow us to establish new contacts.

Given these circumstances, Emotra’s move to AstraZeneca BioVentureHub will boost our progress by giving us access to a larger, more suitable infrastructure and support networks. Furthermore, it provides us with more possibilities to interact with new research actors, with a large focus on collaboration.

Within the framework of a previous collaboration, our EUDOR-A study, we have now submitted our paper to a scientific journal. No publication date has yet been set, as the article needs to go through the review process that this type of scientific publication stipulates.

In 2020, we will continue to focus on collaborations with various parties, with the goal of verifying the findings concerning depression relapse. This new indication area, the possibility of documenting other risks associated with hyporeactivity, and increased awareness about the biological basis for our method all open interesting opportunities for Emotra.

For further information about the Company, please contact: Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca Bio Venture-Hub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden
Tel: +46 73 234 41 93, www.emotra.se